share_log

Structure Therapeutics | 8-K: Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity

Structure Therapeutics | 8-K: Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity

碩迪生物 | 8-K:Structure Therapeutics 公佈 2024 年第三季度財務業績和近期亮點 ACCESS 20期 GSBR-1290 肥胖症研究首次給藥的患者
美股SEC公告 ·  11/13 15:17
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息